The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”).

The following table summarizes the total share-based compensation expense associated with the Company’s stock options, RSUs and DSUs for the three months ended March 31, 2026 and 2025:


	Three months ended March 31,
	2026		2025
Stock options	$	18	$	74
RSUs	1,338		2,014
DSUs	(43)		—
Total share-based compensation	$	1,313	$	2,088

Share-based compensation for the three months ended March 31, 2026 included a gain of $43 associated with the Company’s DSUs. For the three months ended March 31, 2025, a gain of $117 was included in revaluation of financial instruments in the Company’s condensed consolidated statements of net income (loss) and comprehensive income (loss), related to the revaluation of DSUs.

Vesting conditions for grants of options are determined by the Compensation Committee of the Board. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three to five years with a maximum term of ten years. The 2020 Omnibus Plan does not authorize grants of options with an exercise price below fair market value.

The following is a summary of the changes in stock options for the three months ended March 31, 2026 and 2025:


	Weighted-average exercise price (C$) (i)		Number of options	Weighted-average remaining contractual term (years)
Balance as of December 31, 2025	$	5.68	588,317	2.48



Balance as of March 31, 2026	$	5.68	588,317	2.24
Exercisable as of March 31, 2026	$	5.92	541,237	2.09


	Weighted-average exercise price (C$) (i)		Number of options	Weighted-average remaining contractual term (years)
Balance as of December 31, 2024	$	5.63	717,264	3.65



Balance as of March 31, 2025	$	5.63	717,264	3.40
Exercisable as of March 31, 2025	$	6.20	573,253	3.04

(i)The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.


	As of March 31, 2026	As of December 31, 2025
2020 Omnibus Plan	588,317	588,317


Total stock options outstanding	588,317	588,317

The following is a summary of the changes in RSUs for the three months ended March 31, 2026 and 2025:


	Weighted-average grant date fair value (C$)(ii)		Number of RSUs
Balance as of December 31, 2025	$	2.85	5,385,106
Granted(i)	3.49		1,507,369
Vested and issued	2.66		(1,635,895)

Balance as of March 31, 2026	$	3.05	5,256,580


	Weighted-average grant date fair value (C$)(ii)		Number of RSUs
Balance as of December 31, 2024	$	3.50	8,382,213
Granted(i)	2.73		1,775,668
Vested and issued	4.00		(4,459,280)
Cancellation and forfeitures	3.47		(134,999)
Balance as of March 31, 2025	$	2.86	5,563,602

(i)RSUs granted in the period vest annually in equal installments over a three-year period from the grant date. All RSUs are subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.

(ii)The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.

The following is a summary of the changes in DSUs for the three months ended March 31, 2026 and 2025:


	Financial liability		Number of DSUs
Balance as of December 31, 2025	$	1,993	758,499


Gain on revaluation	(43)		—
Foreign exchange effect	(31)		—
Balance as of March 31, 2026	$	1,919	758,499


	Financial liability		Number of DSUs
Balance as of December 31, 2024	$	1,129	560,261


Gain on revaluation	(117)		—
Foreign exchange effect	(3)		—
Balance as of March 31, 2025	$	1,009	560,261